Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ajanta Pharma's share price for the quarter that ended in Jun. 2026 was ₹3422.7. Ajanta Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 125 Mil. Therefore, Ajanta Pharma's market cap for the quarter that ended in Jun. 2026 was ₹427,618 Mil.
Ajanta Pharma's quarterly market cap
increased
from Dec. 2025 (₹346,104 Mil) to Mar. 2026 (₹350,258 Mil) and
increased
from Mar. 2026 (₹350,258 Mil) to Jun. 2026 (₹427,618 Mil).
Ajanta Pharma's annual market cap
increased
from Mar. 2024 (₹281,813 Mil) to Mar. 2025 (₹327,082 Mil) and
increased
from Mar. 2025 (₹327,082 Mil) to Mar. 2026 (₹350,258 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ajanta Pharma's Enterprise Value for Today is ₹430,947 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ajanta Pharma Market Cap Related Terms
Ajanta Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Ajanta Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ajanta Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (BOM:532331) has a Market Cap of ₹434,976 Mil as of Sep. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ajanta Pharma and its competitors. According to the industry distribution chart, Ajanta Pharma ranks #82 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Ajanta Pharma's Market Cap too high?
Ajanta Pharma's current Market Cap is ₹434,976 Mil. Based on the distribution chart, Ajanta Pharma ranks #82 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #82 out of 1023 companies for Market Cap. This places Ajanta Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 235.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 235.32, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 235.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current Market Cap is ₹434,976 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (BOM:532331) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,480.95 — trading 4% above its estimated fair value. The current Market Cap is ₹434,976 Mil. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ajanta Pharma (BOM:532331), the current Market Cap is ₹434,976 Mil as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (BOM:532331) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,480.95 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for BOM:532331:
Market Cap: ₹434,976 Mil
GF Value™: ₹3,348.50 vs. price of ₹3,480.95 (4% above fair value)
No single metric tells the full story. See the BOM:532331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for BOM:532331
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532331 has been successfully added to your 
